Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001199212 | SCV001370234 | pathogenic | Age related macular degeneration 2 | 2019-02-27 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS1,PM1,PM2,PP2,PP3,PP5. |
Labcorp Genetics |
RCV001861442 | SCV002232699 | pathogenic | not provided | 2023-12-28 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 230 of the ABCA4 protein (p.Cys230Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Stargardt disease (PMID: 10958763, 11702214, 15192030; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 373916). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABCA4 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Centre for Mendelian Genomics, |
RCV000415009 | SCV000492544 | likely pathogenic | Visual impairment; Central scotoma; Macular degeneration; Retinal atrophy | 2016-06-12 | no assertion criteria provided | clinical testing |